The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives.
Given the many thrombolytic agents and the number of ways in which they can be combined with mechanical revascularization, the treatment of acute myocardial infarction has been the subject of active study and lively debate, which are likely to continue for some time. Several studies, including TIMI IIA (2,3,10,22), have suggested that immediate catheterization and angioplasty offer no clinical benefit and have a greater complication rate than a more delayed invasive strategy, but TIMI II (1) and SWIFT (16) trials have suggested that an even more conservative strategy of reserving catheterization and coronary angioplasty after thrombolytic therapy for patients with recurrent spontaneous or exercise-induced ischemia may be the most desirable approach for the majority of patients similar to those entered into these trials.
Baim
D S
DS
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Braunwald
E
E
Feit
F
F
Knatterud
G L
GL
Passamani
E R
ER
Robertson
T L
TL
Rogers
W J
WJ
Solomon
R E
RE
Williams
D O
DO
D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D006328:Cardiac Catheterization; D017023:Coronary Angiography; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D010360:Patient Transfer; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D010959:Tissue Plasminogen Activator; D001241:Aspirin